Oncolytics Biotech Income Statement

Financials in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Selling, General & Admin	16.02	13.34	16.08	11.49	13.32	12.51
Research & Development	18.96	21.65	17.71	15.43	12.92	12.95
Operating Expenses	34.98	34.98	33.79	26.92	26.24	25.46
Operating Income	-34.98	-34.98	-33.79	-26.92	-26.24	-25.46
Interest & Investment Income	0.48	1.2	1.33	0.53	0.1	0.12
Currency Exchange Gain (Loss)	0.19	0.96	-0.48	1.67	-0.14	-0.66
Other Non Operating Income (Expenses)	-1.1	1.24	5.29	-0.02	0.02	3.49
EBT Excluding Unusual Items	-35.41	-31.58	-27.66	-24.75	-26.26	-22.51
Pretax Income	-35.41	-31.58	-27.66	-24.75	-26.26	-22.51
Income Tax Expense	-0.14	0.13	0.1	0.08	0.05	-
Net Income	-35.27	-31.71	-27.75	-24.84	-26.3	-22.51
Net Income to Common	-35.27	-31.71	-27.75	-24.84	-26.3	-22.51
Shares Outstanding (Basic)	89	76	68	58	54	40
Shares Outstanding (Diluted)	89	76	68	58	54	40
Shares Change (YoY)	17.39%	13.10%	16.53%	8.44%	32.66%	82.22%
EPS (Basic)	-0.40	-0.41	-0.41	-0.43	-0.49	-0.56
EPS (Diluted)	-0.40	-0.41	-0.41	-0.43	-0.49	-0.56
Free Cash Flow	-26.48	-27.21	-28.46	-23.41	-22.72	-22.1
Free Cash Flow Per Share	-0.30	-0.36	-0.42	-0.40	-0.42	-0.55
EBITDA	-34.9	-34.88	-33.71	-26.83	-26.11	-25.37
D&A For EBITDA	0.09	0.1	0.08	0.09	0.13	0.09
EBIT	-34.98	-34.98	-33.79	-26.92	-26.24	-25.46

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q